P-907. Burden of Hospitalization for Coccidioidal Meningitis: A National Cohort Study
Authors: Coleman Craig I , Donovan Fariba , Miriyapalli Lahar , Shan Ryan M , Bresnik Mark , Lovelace Belinda 
Published: January 2025

Background

Coccidioidal meningitis (CM) is a severe complication of an endemic fungal infection requiring life-long aggressive medical and often surgical management necessitating hospitalization. Few data evaluating the burden of CM on hospitals have been published. This report assesses inpatient healthcare utilization, total costs, and mortality in hospitalized CM patients.Table 1:Demographics, Comorbidities and Outcomes of Patients Admitted with Coccidioidal MeningitisCI=confidence intervals; CM=coccidioidal meningitis†Primary diagnosis code for a common meningitis complication including hydrocephalus, cerebral vascular accident, encephalitis, encephalopathy, cerebral vasculitis or vasospasm, cerebral abscess, shunt complication, infusion device failure.*Includes ventricular shunt, drain or infusion device placement, revision, or

removal.

Methods

We used the National Inpatient Sample (NIS) to evaluate CM hospitalizations for the years 2019 t0 2021. The NIS is a 20% stratified systematic randomized sampling of all hospital discharges, drawn from States participating in the Healthcare Utilization Project (HCUP) (including all states in which coccidioidomycosis is endemic) and covering &gt;97% of the US population. The sample weighted to reflect all hospitalizations in the US per year. CM was identified by the International Classification of Diseases-10th Revision (ICD-10) diagnosis code of B38.4 in any coding position. All analyses were performed on the weighted population using methods prescribed by HCUP. We estimated frequencies or mean/median values for demographics, comorbidities, need for CM-related procedures (i.e., ventricular shunt, drain or infusion device placement, revision, or removal), inpatient mortality, length-of-stay (LOS), and all cause total hospital costs (in 2023 US$) with 95% confidence intervals (CIs).

Results

We identified 2,305 CM hospitalizations (Table 1). The annual rates of CM hospitalizations ranged from 2.7-3.2 per million Americans for the three years studied. The mean age of CM patients was ∼48 years, most were men (73.3%) and occurred in the West census region (89.7%). Concurrent pulmonary coccidioidomycosis was present in 18.2% of patients. In total, 63.6% (59.3-67.6%) of patients required a CM-related procedure during the stay and 7.6% (5.6-10.3%) died prior to discharge. Mean LOS was 13.0 days (11.3-14.6) and mean hospital costs were $48,155 ($42,382-$53,929) per stay.

Conclusion

Hospitalization of CM patients in the US are associated with substantial medical and economic burden. The complex management and high costs associated with CM suggest a need for novel management approaches including novel antifungal treatments.

Disclosures

Craig I. Coleman, PharmD, F2G Ltd: Advisor/Consultant|F2G Ltd: Grant/Research Support Fariba Donovan, MD, PhD, F2G: Advisor/Consultant|F2G Ltd: Advisor/Consultant|F2G Ltd: Grant/Research Support|F2G Ltd: Honoraria Mark Bresnik, MD, F2G Ltd: Employee Belinda Lovelace, PharmD, MS, MJ, F2G, Inc.: Employee